Foghorn Therapeutics Newsroom

TD Cowen Maintains Foghorn Therapeutics(FHTX.US) With Buy Rating

Futu NewsNov 5 21:35

H.C. Wainwright Maintains Foghorn Therapeutics(FHTX.US) With Buy Rating, Maintains Target Price $20

Futu NewsNov 5 19:36

TD Cowen Maintains Foghorn Therapeutics(FHTX.US) With Buy Rating

Futu NewsNov 5 08:33

TD Cowen Keeps Their Buy Rating on Foghorn Therapeutics (FHTX)

TipRanksNov 5 08:19

Foghorn Therapeutics Analyst Ratings

BenzingaSep 24 19:30

Morgan Stanley Adjusts Foghorn Therapeutics Price Target to $9 From $6, Maintains Equalweight Rating

MT NewswiresSep 23 21:45

Jefferies Initiates Foghorn Therapeutics(FHTX.US) With Buy Rating, Announces Target Price $18

Futu NewsSep 3 17:32

Foghorn Therapeutics Analyst Ratings

BenzingaAug 19 21:57

Evercore ISI Group Initiates Coverage On Foghorn Therapeutics With Outperform Rating, Announces Price Target of $20

BenzingaAug 19 21:57

Evercore Maintains Foghorn Therapeutics(FHTX.US) With Buy Rating, Maintains Target Price $20

Futu NewsAug 19 20:31

Analysts Offer Insights on Healthcare Companies: Equillium (EQ), Foghorn Therapeutics (FHTX) and Immix Biopharma, Inc. (IMMX)

TipRanksAug 19 18:42

Evercore Initiates Foghorn Therapeutics(FHTX.US) With Buy Rating, Announces Target Price $20

Futu NewsAug 19 18:31

Foghorn Therapeutics Drug Candidates FHD-286 and FHD-909 Show Promise in Early Trials, Justifying Buy Rating

TipRanksAug 12 18:44

HC Wainwright & Co. Reiterates Buy on Foghorn Therapeutics, Maintains $20 Price Target

BenzingaAug 12 18:28

Foghorn Therapeutics Price Target Maintained With a $13.00/Share by Wedbush

Dow JonesAug 9 22:14

Foghorn Therapeutics Analyst Ratings

BenzingaAug 9 22:04

Wedbush Keeps Their Buy Rating on Foghorn Therapeutics (FHTX)

TipRanksAug 9 21:36

Analysts Offer Insights on Healthcare Companies: Tango Therapeutics (TNGX), Inozyme Pharma (INZY) and Foghorn Therapeutics (FHTX)

TipRanksAug 8 21:53

HC Wainwright & Co. : The Foghorn Therapeutics (FHTX.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $20.00.

Zhitong FinanceMay 7 18:51

Foghorn Therapeutics Analyst Ratings

BenzingaMay 7 18:50